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http://dx.doi.org/10.1016/j.pedneo.2Mycoplasma pneumoniae (Mp) is one of the main pathogens causing community-acquired pneu-
monia, particularly in young individuals. Host immune response appears to play an important
role in prolonged symptoms, as well as in the recent increasing prevalence of drug-resistant Mp
isolated from patients. Case 1 had a prolonged clinical course caused by drug-resistant Mp and
received steroid therapy despite Mp susceptibility to some antimicrobial agents. Serum cyto-
kine profiles revealed elevation of interleukin-6/-10 and interferon-g in acute phase. Case 2
had mycoplasmal myocarditis without any respiratory symptoms, which resolved spontane-
ously without the administration of any antimicrobial agent. These observations suggest that
host immune response probably contributes to the etiology of Mp-associated complications.
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Mycoplasma-associated complications in 2010 4031. Introduction hospitalization. Physical examination on admissionMycoplasma pneumoniae (Mp) is one of the main pathogens
causing community-acquired pneumonia in children, espe-
cially in those of school age. Macrolide (ML) antibiotics are
usually considered to be the first choice for the treatment of
Mp infections. However, the prevalence of ML-resistant Mp
isolates in pediatric patients has been increasing rapidly,
with a confirmed 23S rRNAmutation. In 2008, the prevalence
was reportedly 30.0% in Japan1 and 70% in China.2 Although
no significant differences between prolonged clinical
symptoms and drug resistance have been reported previ-
ously, host immune response has been recognized as
contributing to severity. Serum cytokine profiles revealed
high levels of inflammatory cytokines such as interleukin
(IL)-6/-10 and interferon (IFN)-g,3,4 with a study including
the finding of a significant association between serum level
of IL-18 and severity of Mp pneumonia in children.5
Herein, we present two patients with interesting char-
acteristics to report clinical aspects of Mp-associated
complications in the 2010 epidemic season.
2. Case Reports
2.1. Case 1
A previously healthy 9-year-old boy, with a 6-day history of
high fever and dry cough, was brought to our department
and admitted in December 2010. He had received clari-
thromycin (CAM, 10 mg/kg/d) 2 days prior toFigure 1 Clinical course in Case 1. Laboratory data revealed that
after the initiation of steroid therapy. AST Z aspartate aminot
CRP Z C-reactive protein; IFN Z interferon; IL Z interleukin; LD
performed; PSL Z prednisolone; RR Z respiratory rate; sIL-2R Z
WBC Z white blood cell counts.revealed fever (37.8 C), but no rales in either lung on
auscultation. Respiratory distress was not evident from his
respiratory rate (RR, 18/min) or percutaneously measured
oxygen saturation (SpO2, 97%) on room air. A chest roent-
genogram on admission indicated consolidation in the right
middle lobe. A nasopharyngeal swab (NPS) sample was
collected on admission and sent for comprehensive rapid
analysis using real-time polymerase chain reaction (PCR) to
determine the causative pathogen.6 This assay detected Mp
DNA, but no other respiratory bacterial or viral DNA.
Bacterial culture of the same specimen yielded no causa-
tive pathogens.
Vital signs, treatments, and laboratory data during the
clinical course are shown in Figure 1. The patient was treated
with antibiotics [minocycline (MINO), 4 mg/kg/d for 3 days,
and clindamycin, 18 mg/kg/d for 3 days]. Clinical symptoms,
including fever, continuous dry cough, and respiratory
conditions, persisted despite the administration of these
antibacterial agents. The chest radiographic abnormality had
not resolved by Day 11 after the onset. Blood tests revealed
increases in aspartate aminotransferase and lactate dehy-
drogenase (LDH) together with elevations in ferritin and
soluble IL-2 receptor (sIL-2R), without significant hepatic and
renal dysfunctions. These findings and the clinical course
suggest that Mp infection induced host immune response.
Intravenous administration of prednisolone (1.3mg/kg/d) for
3 days was initiated on Day 12 after the onset. The patient
recovered rapidly after steroid administration and was dis-
charged onDay 16 after the onset. No recurrencewas evident
at follow-up assessment on Day 20.elevations of serum IFN-g and IL-6/-10 concentrations resolved
ransferase; BT Z body temperature; CLDM Z clindamycin;
H Z lactate dehydrogenase; MINO Z minocycline; NP Z not
soluble interleukin-2 receptor; TNF Z tumor necrosis factor;
Figure 2 Electrocardiographic changes in Case 2. Arrows indicate elevation of ST wave (V2e6) on Day 3, negative T wave (V2e4)
on Day 4, and positive T wave (V2e4) on Day 7 after onset of symptoms, respectively. Decrease of T wave (V5 and V6) on Day 7 also
was observed.
404 T. Takei et alOn Day 19 after the onset, the MP strain was isolated
from the NPS sample obtained on admission for the
determination of minimal inhibitory concentrations (MICs).
Susceptibility tests using microdilution methods with
pleuropneumonia-like organism broth, as previously
described,7 showed MICs of MINO and levofloxacin of 0.25
and 0.5 mg/mL, respectively, suggesting the absence of
drug resistance. On the other hand, MICs of erythromycin,
CAM, azithromycin, telithromycin, and rokitamycin were
>64, >64, 32, 64, and 0.125 mg/mL, respectively. Genetic
analysis data for the strain indicated amino acid substi-
tution A2063G in domain V of 23S rRNA. In this case,
we confirmed that the causative pathogen was ML-
resistant Mp.
Serum samples were obtained on Days 11, 13, and 16
after the onset. Circulating levels of seven inflammatory
cytokines were measured using a BD CBA kit (Becton-Dick-
inson Biosciences, San Diego, CA, USA), together with a BD
cytometric bead array system (Becton-Dickinson Biosci-
ences). Serum concentrations of IFN-g, IL-6, and IL-10 were
increased on Day 11 and decreased after steroid
administration.2.2. Case 2
In December 2010, a previously healthy 13-year-old girl was
brought to our department with a 3-day history of fever and
chest pain. Vital signs were as follows: body temperature,
37.7C; heart rate, 88/min, regular; RR, 18/min; SpO2, 97%
on room air; and blood pressure, 113/70 mmHg. Physical
examination revealed neither any significant cardiac
murmurs nor any pericardiac rubs. A chest roentgenogram
on admission indicated no significant cardiomegaly and
consolidations in the lung. Laboratory findings includedelevated serum concentrations of creatine kinase (CK,
398 IU/L and CK-MB 34 IU/L) and C-reactive protein (CRP,
4.9 mg/dL), and a positive troponin-T reaction, all sug-
gesting cardiac involvement. Elevation of SeT waves in
leads V2e6 also suggested cardiac involvement. Echocar-
diography showed mild left ventricular hypertrophy and
mitral valve regurgitation (Grade I), but no significant
pericardial effusion or coronary dilation. The patient was
diagnosed as having myocarditis and was admitted to our
department immediately. The chest pain and fever
resolved spontaneously, with improvements in laboratory
findings (e.g., serum levels of CK and CRP decreased). Mp
infection was diagnosed with a four-fold elevation of anti-
body titers against Mp (particle agglutination method) on
Days 3 and 7. At discharge, echocardiography showed no
effusions or regurgitation involving the left ventricle.
Figure 2 summarizes the electrocardiographic changes.
We analyzed changes of viral antibodies in both acute
and convalescent phases. These analyses included anti-
bodies against coxsackie virus A type (2e7, 9, and 10) and B
type (1e5), cytomegalovirus, and influenza virus (H1N1,
H3N2, and B), but no significant elevations were observed.3. Discussion
ML-resistant Mp infection in Case 1 induced prolonged clin-
ical course even though a drug to which the organism was
susceptible had been administered. Amino acid substitution
(A2063G) of 23Sr rRNA in the isolate is the most prevalent
pattern, and its prevalence is increasing. In 2011, the
prevalence of ML-resistant Mp strain among children with
community-acquired pneumonia in Japanwas reported to be
89.5% (68 of 76 strains).8 The rapidly increasing prevalence
seems to be due to transport of the resistant strains from
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business. This strain was resistant to CAM but susceptible to
MINO. However, an antimicrobial therapy did not ameliorate
symptoms. We speculate that the immune response might
have contributed to this patient’s prolonged clinical course.
It was reported that inflammatory cytokines including IL-8/-
18 and IFN-g play important etiological roles.4,5,9 High serum
levels of sIL-2R, IL-6, and IL-10 were reported in severe Mp
infection, presenting as hemophagocytic syndrome.3 We
confirmed elevations of serum cytokines, together with high
serum concentrations of ferritin, sIL-2R, and LDH, which also
suggested host immune response. Oishi et al5 reported
a relationship between IL-18 and LDH in Mp pneumonia: the
LDH value of 480 IU/L corresponds to the IL-18 value of
1000 pg/mL, which is an appropriate level to begin steroid
administration for Mp pneumonia. We could not measure
serum IL-18 levels in Case 1. However, a maximum LDH value
of 561 IU/L may reflect elevation of serum IL-18 level, which
is a reasonable criterion for starting steroid administration.
In fact, Case 1 responded well to the steroid treatment.
These findings suggest that prolonged Mp infection did not
result from drug resistance, but rather from host immune
response. The treatment option for ML-resistant Mp pneu-
monia appears to be MINO, but it is not recommended for
pediatric patients aged 8 years or younger.8 Definitive proof
of efficacy and safety of steroid administration to ML-
resistant Mp-infected children when treating the prolonged
symptoms will require a randomized trial.
Myocarditis caused by Mp infection in Case 2 improved
spontaneously without any respiratory tract infectious
symptoms. The symptoms in this case were similar to those
of viral myocarditis such as coxsackie virus B type infection.
However, Case 2 did not progress to a severe state with
arrhythmias or acute cardiac failure. Izumi10 reported that
coxsackie B viruses were the most common causative
pathogens, while only 4% of myocarditis cases were caused
by Mp infection. Morimoto et al11 reported 24 cases of
myocarditis caused by Mp infection, 13 (54.2%) of whom
were 15 years and younger. They reported myocarditis,
which was caused by Mp infection, to have a good prognosis
because only one patient died. Only two cases (8.3%)
developed grade III atrioventricular block or abnormal Q
waves, suggesting relatively mild cardiac injuries as
compared to viral infections.
Case 2 showed spontaneous recovery and mild clinical
features, including mild hypertrophy involving the left
ventricular muscle and mild mitral valve regurgitation.
Furthermore, she did not develop severe heart failure
despite not receiving an antimicrobial agent. It seemed
that host immune response occurred against Mp infection.
Of 24 patients with Mp-associated myocarditis, 23
showed rhinitis and 12 had pneumonia.11 We did notperform real-time PCR assay for the detection of Mp DNA,
instead of evidence concerning the four-fold elevation of
antibody titers. The respiratory tract is considered to be
the transmission pathway of Mp. If the patient shows
symptoms related to myocarditis during the Mp epidemic
season, collecting nasopharyngeal samples is useful to
clarify the causative pathogen by real-time PCR assay.References
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